Trial reportCNS drugs2023
Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use.
Trial report in CNS drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 44 citations in OpenAlex.
- ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia Gravis.Annals of clinical and translational neurology · 2025Trial
- Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants.Drugs in R&D · 2024Trial
- Investigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administered with a Prefilled Syringe.Advances in therapy · 2026Article
- Targeting FcRn for immunomodulation: a promising therapy in autoimmune inflammatory rheumatic diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Efgartigimod in Patients with Generalized Myasthenia Gravis Refractory or Intolerant to IVIg.Neurology and therapy · 2026Article
- B Cells and B Cell Depletion in Autoimmunity and Atherosclerosis.Life (Basel, Switzerland) · 2026Review
- Efgartigimod Alfa as a novel rescue therapy for severe NMOSD: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Recurrent steroid-intolerant Hashimoto's encephalopathy responsive to single-dose neonatal Fc receptor antagonist: a case report and literature review.BMC neurology · 2026Review
- Rapid efficacy of efgartigimod for generalized myasthenia gravis patients in acute exacerbations/worsening: multicenter real-world retrospective study.Journal of neurology · 2026Article
- Real-world experience with efgartigimod in generalized myasthenia gravis: a single-center retrospective study in China.Frontiers in immunology · 2026Article
- Evolving Therapeutic Approaches for Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients.Results and problems in cell differentiation · 2026Review
- Article
- Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications.Biomedicines · 2025Review
- Review
- Pharmacovigilance analysis of FcRn antagonists in the treatment of myasthenia gravis: A disproportionality analysis based on the FAERS database.Human vaccines & immunotherapeutics · 2025Article
- Effective Subcutaneous Efgartigimod Treatment in a 90-Year-Old Female With Myasthenia Gravis.Journal of clinical neurology (Seoul, Korea) · 2025Article
- A Comprehensive Approach to Myasthenia Gravis With Thymoma: A Case Report Highlighting Management of Myasthenic Crisis and Post-Crisis Care.Clinical case reports · 2025Article
- Safety and Efficacy of a Neonatal Fc Receptor Antagonist in Patients With Anti-NMDAR Encephalitis.CNS neuroscience & therapeutics · 2025Article
- From promise to practice: evaluating the clinical impact of FcRn inhibition in IgG-mediated autoimmune rheumatic diseases.Frontiers in immunology · 2025Review
- Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study.Therapeutic advances in neurological disorders · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous efgartigimod alfa (also known as efgartigimod alfa-fcab in the USA; Vyvgart
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.